Certificate Of Correction That Broadens Is Invalid
Client Alert | 1 min read | 04.09.07
In Central Admixture Pharmacy Services, Inc. v. Advanced Cardiac Solutions, P.c., (No. 2006-1307, April 3, 2007), the Federal Circuit vacates a finding of patent infringement involving a chemical solution used during heart surgery and remands for redetermination of infringement under the patent’s original claims, uncorrected by an invalid certificate of correction. Summary judgment that the patent is not invalid is, however, affirmed.
The Federal Circuit panel disagrees with the district court’s determination that a certificate of correction of the patent, changing the word “osmolarity” to the word “osmolality” was appropriate. “Osmolarity” is the amount of solute per liter of total solution (mOsmol/L), and “osmolality” the amount of solute per kilogram of solvent (mOsmol/kg). In the asserted claims, a solution having an “osmolarity . . . of between about 400-500 mOsmol” was initially claimed, but was by the certificate to read “osmolality”. Because of the change in the range, the accused solution is more likely to infringe the corrected claims.
Invalidating a certificate of correction for impermissible broadening of the claims, says the panel, requires proof that the corrected claims are broader than the original claims, and that the presence of the error in the original claims, or how to correct it, is not clearly evident to one of skill in the art. The panel reasons that in the original claims, the word “osmolarity” is spelled correctly and reads logically in the context of the sentence. And because the error corrected by the certificate was not clearly evident to one of skill in the art, the result of the correction was to broaden the claims.
Insights
Client Alert | 7 min read | 06.26.26
Federal Roundup: Updates for PBMs and Medicare Advantage Organizations
In June 2026, federal regulators and lawmakers continued their efforts to improve drug affordability through targeted reforms. These recent developments will primarily impact pharmaceutical manufacturers, managed care organizations, and pharmacy benefit managers (PBM) serving Medicare Part D program members. PBMs, Medicare Advantage organizations, and Part D sponsors should monitor these changes in the interest of maintaining compliance and providing input on regulatory proposals that may influence their business operations or compensation structures in the future.
Client Alert | 6 min read | 06.26.26
Client Alert | 4 min read | 06.25.26
Twin Executive Orders Seek to Spur Quantum Leap in Technology and Cybersecurity
Client Alert | 7 min read | 06.24.26
